Idera Pharmaceuticals, Inc. Presents Data on IMO-3100 in Preclinical Lupus Model Showing Suppression of Disease Progression Parameters

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) announced today that it is presenting data on IMO-3100, an antagonist of TLR7 and TLR9, in a preclinical model of lupus showing that treatment with IMO-3100 suppressed several key disease progression parameters. The presentation, entitled “Treatment with IMO-3100, a novel TLR7 and TLR9 antagonist, inhibits disease development in lupus prone NZBW/F1 mice,” is being made at the Keystone Symposia: Dendritic Cells and the Initiation of Adaptive Immunity being held February 12-17, 2011 in Santa Fe, New Mexico.